Abivax
Created in 2013
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
1,288 10,489Activities
Technologies
Entity types
Location
Corporate Office, 11 Bd Haussmann 7, 75009 Paris, France
Paris
France
Employees
Scale: 51-200
Estimated: 81
SIREN
799363718Engaged corporates
8
5 4Added in Motherbase
3 years, 9 months ago
biotech Value proposition
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Abivax also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease.
Obefazimod is an investigational, orally administered, once-daily therapy, which we believe has the potential to be a differentiated treatment option for inflammatory bowel diseases. It is the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. If approved, this therapy has the potential to establish a new therapeutic class currently being referred to as miR-124 enhancers.
R&D, Inflammatory Bowel Desease, Biotechnology, Innovation, Ulcerative colitis, and Crohn's diseaseOriginal language
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Abivax also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease.
Obefazimod is an investigational, orally administered, once-daily therapy, which we believe has the potential to be a differentiated treatment option for inflammatory bowel diseases. It is the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. If approved, this therapy has the potential to establish a new therapeutic class currently being referred to as miR-124 enhancers.
Abivax | Official Website
Abivax is a clinical-stage biotechnology company driven to advance human health by regulating the immune response through the power of microRNA.
https://www.abivax.com/?lang=fr
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Euronext Finance, Financial Services | Euronext Finance, Financial Services | Not capitalistic Partnership Not event 31 May 2022 | | |
 BFM Business Media, Broadcast Media Production and Distribution | BFM Business Media, Broadcast Media Production and Distribution | Other 24 Oct 2023 | | |
 Institut Curie Health, Hospitals and Health Care | Institut Curie Health, Hospitals and Health Care | Other 19 Sep 2017 | | |
 Avolta Finance, Investment Banking | Avolta Finance, Investment Banking | Other 31 Aug 2022 | | |
 Nasdaq Finance, Financial Services | Nasdaq Finance, Financial Services | Other 8 Dec 2023 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 13 Jun 2017 | | |
 Sofinnova Partners Financial Services | Sofinnova Partners Financial Services | Other 18 Nov 2023 | | |
 CNRS Research, Research Services | CNRS Research, Research Services | Not capitalistic Not partnership Event 12 May 2017 | | |